Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 6/20 | 0.74 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.74 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.74 |
| ▸ | FBP1 | P09467 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 7/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661023 | 1.00 | HSPA8 (0.74) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL14380122 | 1.00 | HSPA8 (0.74) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL11574082 | 0.97 | HSPA8 (0.73) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL11574099 | 0.97 | HSPA8 (0.73) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL6758944 | 0.96 | HSPA8 (0.72) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL6758942 | 0.96 | HSPA8 (0.72) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL6762435 | 0.90 | FBP1 (0.79) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL13127208 | 0.90 | HSPA8 (0.80) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL6762443 | 0.90 | FBP1 (0.79) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL6763143 | 0.90 | HSPA8 (0.80) | HSPA8HSPA5RXFP1FBP1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171740-A1 | METHODS FOR GENERATING FUNCTIONAL HEMATOPOIETIC STEM CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2025-05-29 | — | — | US | claimed |
| US-11767523-B2 | Acrylamide copolymerization for sequestration and production of single-stranded nucleic acid | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-09-26 | — | — | US | claimed |
| EP-3383182-B1 | METHODS FOR GENERATING FUNCTIONAL HEMATOPOIETIC STEM CELLS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20110262442-A1 | COMPOSITIONS FOR TREATING CNS DISORDERS | ADENIOS, INC. (US) | 2011-10-27 | — | — | US | claimed |
| CN-122091465-A | Plasma electrospray fusion ionization source and mass spectrum combined system and detection method | — | 2026-05-26 | — | — | CN | disclosed |
| US-12623215-B2 | Method for preparing a monolithic support on which uranyl cations are immobilised, and associated methods for capture and recovery | COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (FR) | 2026-05-12 | — | — | US | disclosed |
| US-20260126354-A1 | TISSUE TRANSFER HYDROGEL DEVICES | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12590053-B2 | Process for preparing vanillin (meth)acrylates | EVONIK OPERATIONS GMBH (DE) | 2026-03-31 | — | — | US | disclosed |
| EP-3986610-B1 | METHOD FOR PREPARING A MONOLITHIC SUPPORT ON WHICH URANYL CATIONS ARE IMMOBILISED, AND ASSOCIATED METHODS FOR CAPTURE AND RECOVERY | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2026-03-04 | — | — | EP | disclosed |
| EP-4211106-B1 | A PROCESS FOR PREPARING VANILLIN (METH)ACRYLATES | EVONIK OPERATIONS GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| EP-3791863-B1 | PROCESS FOR THE PRODUCTION OF HYBRIDOSOMES | ANJARIUM BIOSCIENCES AG (CH) | 2025-09-10 | — | — | EP | disclosed |
| US-20250171740-A1 | METHODS FOR GENERATING FUNCTIONAL HEMATOPOIETIC STEM CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2015013653-A1 | GENERATING DEFINITIVE ENDODERM AND PANCREATIC PROGENITOR CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-01-29 | — | — | WO | disclosed |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | OTONOMY, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2490722-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | Otonomy, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050206-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049960-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049958-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | IKARIA, INC. (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | ADORA2A, ADORA2B, ADORA1 | HSPA8 1006/4885HSPA5 1875/4885RXFP1 265/4885 |
| US-12623215-B2 | Method for preparing a monolithic support on which uranyl cations are immobilised, and associated methods for capture and recovery | ORAI1, STIM1, STIM2 | HSPA8 1245/4885HSPA5 1269/4885RXFP1 3952/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | HSPA8 1036/4885HSPA5 3165/4885RXFP1 294/4885 |
| US-20260126354-A1 | TISSUE TRANSFER HYDROGEL DEVICES | CD68, ACTB, GJA1 | HSPA8 218/4885HSPA5 201/4885RXFP1 1142/4885 |
| US-12590053-B2 | Process for preparing vanillin (meth)acrylates | ADH1A, HVCN1, ADH1C | HSPA8 2139/4885HSPA5 2439/4885RXFP1 4840/4885 |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | PTGIR, HSPH1, HSP90AA1 | HSPA8 15/4885HSPA5 446/4885RXFP1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.